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SI Results
Currently, one of the major limitations in studying p97 function is
the lack of a potent, selective, and reversible small-molecule
inhibitor that has a deﬁned mechanism of action. During the
course of this work, EerI (1) and 2-anilino-4-aryl-1,3-thiazole
(Myriad 12 andMyriad 19) (2) were reported to be p97 inhibitors.
To understand how these compounds compare with DBeQ (N2,
N4-dibenzylquinazoline-2,4-diamine), we evaluated their prop-
erties using our suite of assays (Table S2) (2). In our hands, the
Myriad compounds were less potent p97 inhibitors both in vitro
and in cells (IC50 of 15–40 μM) compared with what has been
reported (3). We do not fully understand the basis for this dis-
crepancy but would like to note that different in vitro assay
methods were used (coupled enzyme assay vs. Biomol Green),
and the cell-based assay used by Bursavich et al. (3) involved
long exposure to compound and monitored accumulation of an
UbG76V-luciferase reporter as opposed to degradation. A po-
tential problem with the accumulation format was noted by
Alvarez-Castelao et al. (4), who demonstrated that accumulation
of three ubiquitin–proteasome system (UPS) reporters in re-
sponse to proteasome inhibitors is driven in large measure by up-
regulation of the constructs’ cytomegalovirus promoter. It is also
worth noting that the Myriad compounds interfere with lucifer-
ase read-outs, which is in agreement with a recent report on
a related scaffold (5). In addition, the Myriad compounds in-
hibited degradation of a p97-independent substrate by 48% at
twofold above the IC50 at which they inhibited degradation of
a p97-dependent substrate (Fig. S7). By comparison, the IC50s of
DBeQ toward p97-dependent and -independent substrates dif-
fered by 20-fold. We identiﬁed the same scaffold (compound 33;
Table S1) as the original Myriad hit in the 218K HTS, but sub-
sequent assays revealed that this hit was of low potency, and it
stabilized both the p97-dependent and -independent reporters.
Thus, although we conﬁrmed that the top Myriad compounds
inhibit p97, they exhibited properties that may compromise their
utility. By contrast, EerI proved to be a speciﬁc inhibitor of
degradation of the p97-dependent reporter in our assays, but this
compound exhibited other characteristics, including interference
with luciferase read-outs and irreversibility, that circumscribe its
use for some applications. Moreover, EerI has been reported to
inhibit other cellular components, including ataxin 3 (1) and
Sec61 (6). Notably, the mechanism by which EerI inhibits p97 is
not understood. Interestingly, EerI did not inhibit ATPase ac-
tivity of puriﬁed p97 (Table S2), and it has been suggested that it
needs to be metabolized into an active compound to exert its
inhibitory effect (1, 6). This could explain why high concen-
trations of EerI are needed to inhibit Sec61-mediated trans-
location in vitro (6).
SI Methods
Materials. Antibodies used in this study were anti-GFP (BD
Biosciences), anti-luciferase (Promega), anti-p97 (Research
Diagnostics), anti-LC3 (Medical Biological Lab), anti–β-actin
(Cell Signaling Technology), anti-Histone H1.0 (Abcam), anti–β-
tubulin (Sigma), anti-p21 (BD Transduction Laboratories), and
anti-CHOP (Cell Signaling Technology). Chemicals used in this
study were MG132 (Biomol), baﬁlomycin A1, and staurosporine
(LC Laboratories), chloroquine and puromycin (Sigma), cyclo-
heximide and Z-VAD(OMe)FMK (EMD Bioscience), and 1541
(ASINEX). Cells were grown on a 96-well cellstar black μclear
bottom plate (ISC Bioexpress) for live-cell imaging on an auto-
mated microscope (ImageXpress Micro; Molecular Devices).
FACS was carried out on an Accuri C6 Flow Cytometer (Accuri
Cytometers). Luciferase intensity was determined on an Analyst
AD plate reader (Molecular Devices). Plasmids for Escherichia
coli recombinant protein expression and mammalian cell trans-
fection, cell lines, and siRNAs used in this study are listed in
Tables S3–S5. All buffers were prepared in deionized water and
ﬁltered through a 0.2-μm ﬁlter.
Recombinant Protein Expression and Puriﬁcation. All buffers were
prepared in deionized water and ﬁltered through a 0.2 μm-ﬁlter.
For recombinant expression of mouse p97, E. coli BL21 (DE3)
containing the desired plasmid was grown in LB medium con-
taining 50 μg/L ampicillin with shaking at 37 °C to an OD600 of
0.5. The cell culture was cooled down to 22 °C and induced with
1 mM isopropyl-beta-D-thiogalactopyranoside and harvested 8–
10 h later by centrifugation. The cell pellet (≈6 g from 2 L) was
suspended in 30 mL lysis buffer [100 mM Tris (pH 7.4), 500 mM
KCl, 5 mM MgCl2, 20 mM imidazole, 5% glycerol, 2 mM
β-mercaptoethanol, and protease inhibitor tablet (Roche)]. The
cells (held in an ice bath) were lysed by six 30-s pulses of soni-
cation, separated by 2-min intervals. The lysate was centrifuged
at 20,000 × g for 45 min at 4 °C, and the resulting supernatant
was loaded onto a Ni-NTA column [5-mL suspension, pre-
equilibrated with wash buffer (50 mL, 50 mM Hepes [pH 7.4],
150 mM KCl, 5 mM MgCl2, and 20 mM imidazole)] and in-
cubated at 4 °C with rotation for 30 min. The column was then
ﬂushed with wash buffer (100 mL), and His6-tagged p97 was
eluted by stepwise application of 10 mL of imidazole elution
buffer (50 mM, 100 mM, 150 mM, 200 mM, or 250 mM imid-
azole in wash buffer). Fractions from the 200-mM and 250-mM
imidazole steps were combined and concentrated with an Ami-
con Ultra-15 centrifugal ﬁlter unit (nominal molecular weight
limit = 100 kDa). The mixture (0.5 mL of 20 mg/mL) was then
fractionated with a gel ﬁltration column (Tricorn Superdex 200;
GE Healthcare), eluted with GF buffer [20 mM Hepes (pH 7.4),
250 mM KCl, and 1 mM MgCl2] at 0.5 mL/min ﬂow rate, and
fractions corresponding to an apparent molecular weight of 500–
600 kDa were collected and analyzed by 4–12% SDS/PAGE to
evaluate purity (Invitrogen). Fractions that contained p97 of
≥95% purity were concentrated to 5 mg/mL, exchanged into
storage buffer [20 mM Hepes (pH 7.4), 250 mM KCl, 1 mM
MgCl2, 5% glycerol, and 1 mM DTT], aliquoted, frozen in liquid
nitrogen, and stored at −80 °C.
High-Throughput Screening (HTS) Assay Reagents. Kinase-Glo
(Promega, part K1214) was purchased from Promega. Microtiter
plates (1,536 wells) were purchased from Greiner. All chemicals
were from Sigma-Aldrich unless otherwise stated. Tris was from
Invitrogen. The Molecular Libraries Small Molecule Repository
(MLSMR) library was provided by BioFocus DPI through the
National Institutes of Health’s Roadmap: Molecular Libraries
Initiative. Details regarding compound selection for this library can
be found online at http://mli.nih.gov/mli/compound-repository/
mlsmr-compounds/. Brieﬂy, the MLSMR library is a highly di-
versiﬁed collection of small molecules (more than 50% of com-
pounds exhibit molecular weights between 350 and 410 g/mol)
comprising both synthetic and natural products, from either com-
mercial or academic sources, that can be grouped into the three
following categories: (i) specialty sets of known bioactive com-
pounds, such as drugs and toxins, (ii) focused libraries aimed at
speciﬁc target classes, and (iii) diversity sets covering a large area
of the chemical space.
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HTS p97 Microtiter Plate Assay. HTS campaign experiments were
executed on a GNF/Kalypsys HTS platform, using integrated
liquid handlers, incubators, and a Viewlux multimode plate
reader (Perkin-Elmer). Before the start of the assay 2.5 μL of
Assay Buffer [1 mM DTT, 50 mM Tris HCl, 20 mM MgCl2, and
1 mM EDTA (pH 8.0), ﬁltered at 0.22 μm] was dispensed into
columns 1 and 2 of 1,536-well assay plates. The remaining 46
columns were ﬁlled with 2.5 μL of Assay Buffer supplemented
with 0.42 μM p97 protein. Next, 40 nL of test compounds (8 μM
ﬁnal nominal concentration) or DMSO alone (0.8% ﬁnal con-
centration) was distributed into the appropriate wells. The plates
were then incubated for 30 min at 25 °C. The assay was started by
the addition of 2.5 μL of 10 mM Tris supplemented with 10 μM
ATP to all wells. The plates were then incubated for 3 h at 25 °C.
After incubation, 5 μL of Kinase Glo reagent was added to all 48
columns, and plates were incubated for another 10 min at 25 °C.
Plates were centrifuged, and luminescence was measured by the
ViewLux microplate reader.
HTS Assay Quality Control and Data Analysis. Raw data from the
ViewLux plate reader were uploaded to an institutional HTS
database (MDL Information Systems). Three quality control
parameters were calculated during the screening on a per-plate
basis: (i) the signal-to-basal ratio (S/B); (ii) the coefﬁcient for
variation [CV; CV = (SD/mean) × 100] for all compound test
wells; and (iii) Z- or Z′-factor [Z′-factor = 1 – [[3 × (σp + σn)]/
(μp – μn)], where σ is the SD and μ the mean for positive (p) and
negative (n) controls] (7).
The percent inhibition for each compound was calculated using
the following mathematical expression:
% Inhibition = [1-(Test_Compound −Median_High_Control)/
(Median_Low_Control − Median_High_Control)] × 100
where “Test_Compound” is deﬁned as wells containing test
compound, “Low_Control” is deﬁned as wells containing DMSO,
and “High_Control” is deﬁned as wells containing no p97 protein.
A mathematical algorithm was used to determine nominally
inhibiting compounds in the primary screen (8). Two values were
calculated: (i) the average percent inhibition of all compounds
tested, and (ii) three times their SD. The sum of these two values
was used as a cutoff parameter; that is, any compound that ex-
hibited greater percent inhibition than the cutoff parameter (i.e.,
exhibiting inhibition >14.53%) was declared active. From the
217,968 MLSMR compounds tested in the primary screen, 923
compounds were declared to be active. Of the 923 active com-
pounds, 759 were available from the MLSMR and ordered for
retesting to conﬁrm activity.
The conﬁrmation assay was run in the exact same conditions as
the primary HTS, except that the 759 compounds were tested in
triplicate and activity values for each compound were reported as
the average percentage activation of the three measurements, plus
or minus the associated SD. Using the same cutoff parameter as
that for the primary HTS, 333 compounds conﬁrmed activity.
Results of the HTS campaign are available from the PubChem
database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=pcassay&
term=p97). Alternatively, the Assay Identiﬁer number (AID)
1481 can be used to search for the primary p97 HTS screen results
in PubChem and AID1517 for the conﬁrmation assay results.
HTS Assay for PubChem AID1534.Before the start of the assay 18 μL
of Assay Buffer [1 mM DTT, 50 mM Tris HCl, 20 mM MgCl2,
and 1 mM EDTA (pH 8.0), ﬁltered at 0.22 μm] was dispensed
into columns 1 and 2, rows O and P of 384-well assay plates. The
remaining wells were ﬁlled with 18 μL of Assay Buffer supple-
mented with 0.42 μM p97 protein. Next, 50 nL of test compounds
or DMSO alone (0.8% ﬁnal concentration) were distributed into
the appropriate wells. The plates were then incubated for 15 min
at 25 °C. The assay was started by the addition of 1 μL of 10 mM
Tris supplemented with 100 μM ATP to all wells. The plates
were then incubated for 1 h at 25 °C. After incubation, 20 μL of
Kinase Glo reagent was added to all 24 columns, and plates were
incubated for another 10 min at 25 °C. Plates were centrifuged,
and luminescence was measured by the Envision microplate
reader. The percent inhibition for each compound was calcu-
lated using the mathematical expression described above.
For each test compound, percent inhibition was plotted against
compound concentration. A four-parameter equation describing
a sigmoidal dose–response curve was then ﬁtted with adjustable
baseline using Assay Explorer software (MDL Information Sys-
tems). The reported IC50 values were generated from ﬁtted
curves by solving for the X-intercept value at the 50% inhibition
level of the Y-intercept value. In cases where the highest con-
centration tested (i.e., 50 μM) did not result in >50% inhibition,
the IC50 was determined manually as >50 μM. Compounds with
an IC50 >10 μM were considered inactive. Compounds with an
IC50 ≤10 μM were considered active.
Any compound with a percent inhibition value <50% at all test
concentrations was assigned an activity score of 0. Any com-
pound with a percent inhibition value >50% at any test con-
centration was assigned an activity score greater than 0. Activity
score was then ranked by the potency, with the most potent
compounds assigned the highest activity scores. Activity scores
for the active compounds of this assay have a range of 22–100,
and all inactive compounds are assigned an activity score of 0.
Manual ATPase Assay. Assay Buffer [20 μL of 2.5× concentration,
where 1× = 50 mM Tris (pH 7.4), 20 mM MgCl2, 1 mM EDTA,
and 0.5 mM tris(2-carboxyethyl)phosphine (TCEP)] was dis-
pensed into each well of a 96-well plate. Puriﬁed p97 (25 μL of
50 μM) was diluted in 975 μL of 1× Assay Buffer, and 10 μL was
dispensed in each well. Test compound (10 μL) or 5% DMSO
(10 μL) was then added to each well, and the plate was incubated
at room temperature for 10 min. The ATPase assay was carried
out by adding to each well 10 μL of 500 μM ATP (pH 7.5), in-
cubating at room temperature for 60 min, and then adding 50 μL
Kinase Glo Plus reagent (Promega), followed by a ﬁnal 10-min
incubation at room temperature in the dark. Luminescence was
read on an Analyst AD (Molecular Devices). Compounds were
assayed at a range of concentrations (0, 0.048, 0.24, 1.2, 6, and 30
μM) in triplicate. The percent of remaining activity for each
reaction was calculated using the following mathematical
expression: [(Test Compound − High Control)/(Low Control −
High Control)] × 100. Test_Compound is deﬁned as wells con-
taining test compound, Low_Control is deﬁned as wells con-
taining DMSO, High_Control is deﬁned as wells containing no
p97 protein. IC50 values were calculated from ﬁtting the per-
centage of remaining activity (%RA) with various concentrations
of compounds to a Langmuir equation [%RA = 100/(1 +
[Compound]/IC50)] by nonlinear regression analysis using the
JUMP IN program. The result was expressed as mean ± SE. For
assaying with N-ethylmaleimide–sensitive factor (NSF) protein,
reaction time was 1.5 h after addition of ATP.
For assays with EerI, Myriad 12, 19, and oxidized Myriad 12,
50 μL of Biomol Green reagent (Enzo Life Sciences) was added
to each well instead of kinase Glo Plus (Promega), and absor-
bance at 630 nm was measured. This was done because these
compounds interfered with luciferase activity. The Lineweaver-
Burk plot of the competitive inhibition of p97 (50 nM) by DBeQ
(0, 0.63, 2.5, and 10 μM) was carried out with various ATP
concentrations (50–700 μM) in Assay Buffer containing 0.01%
Triton X-100, and ATPase activity was determined by addition of
Biomol Green reagent.
Reporter Degradation Assay. Two dual reporter stable HeLa cell
lines were used and are described elsewhere (2). One expressed
the UFD reporter UbG76V-GFP (9) and the oxygen-dependent
degradation domain of HIF1α fused to luciferase (ODD-Luc)
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(10) and the second expressed UbG76V-GFP and luciferase fused
to the ubiquitin-independent degradation domain of ornithine
decarboxylase (Luc-ODC) (10). Trypsinized cells were aliquoted
into each well of a 96-well plate (5,000 cells/well) and grown for
16 h. Cells were treated with modiﬁed DMEM (without phenol
red, folic acid, riboﬂavin, and vitamin B12) containing MG132
(4 μM) for 1 h and washed with prewarmed PBS (100 μL) twice.
Modiﬁed DMEM containing FBS (2.5%), cycloheximide (30 μg/
mL), and DMSO or a test compound (0–30 μM) was added into
each well. Plates were imaged on the ImageXpress Micro at
different time points. For the ODD-Luc or Luc-ODC turnover
assay, four identical 96-well white solid-bottom plates were
prepared. At each time point, one plate was taken out from the
incubator and luciferase activity measure on Analyst AD.
Human 26S Proteasome Activity Assay. Inhibition of hydrolysis of
the ﬂuorogenic proteasome substrate (succinyl-Leu-Leu-Val-Tyr-
AMC, 60 μM; Boston Biochem) by puriﬁed human 26S pro-
teasome (1 nM) from Enzo Life Science in Assay Buffer con-
taining ATP [50 mM Tris (pH 7.4), 20 mMMgCl2, 1 mM EDTA,
0.5 mM TCEP, and 100 μM ATP]. Fluorescence intensity was
monitored every 5 min over 60 min. IC50 values were calculated
from ﬁtting the %RA with various concentrations of compounds
to a Langmuir equation [%RA = 100/(1 + [Compound]/IC50)]
by nonlinear regression analysis using the JUMP IN program.
The result was expressed a mean ± SE.
Kinase Proﬁling. Pyrazolopyrimidine (ACJI-47; Table S2) is an
adenine mimetic kinase inhibitor (11) and was synthesized ac-
cording to the published procedure (12). TheATP acyl-phosphate
probe was synthesized as described previously, except that des-
thiobiotin was substituted for biotin (13). Human HuH7 cell
pellets were lysed in 25 mM Tris (pH 7.6), 150 mM NaCl, 1%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 1% Tergitol Nonidet P-40 type, and 1% vol/vol phos-
phatase inhibitor mixture II (EMD/Calbiochem, #524625) with
a tip sonicator and then cleared by centrifugation at 100,000 × g
for 30 min. Cleared lysates were gel ﬁltered (BioRad 10DG) into
reaction buffer [20 mM Hepes (pH 7.8), 150 mM NaCl, 0.1%
triton X-100, and 1% vol/vol phosphatase inhibitor mixture II] to
remove endogenous nucleotides. After gel ﬁltration, lysates were
adjusted to a 5-mg/mL concentration, and MnCl2 was added to
a ﬁnal concentration of 20 mM. Gel-ﬁltered lysate was incubated
with either DBeQ (15 μM), ACJI-47 (15 μM), or vehicle control
for 15 min, followed by labeling with the ATP acyl-phosphate
probe (5 μM) for 10 min. Labeled samples were denatured and
reduced in 6 M urea, 10 mM DTT at 65 °C for 15 min, and then
alkylated with 40 mM iodoacetamide at 37 °C for 30 min. After
another gel-ﬁltration step to remove excess probe and processing
reagents, the samples were digested with trypsin (0.015 mg/mL) at
37 °C for 1 h. Desthiobiotinylated peptides were isolated on
streptavidin resin and eluted in a 50% CH3CN/water mixture
containing 0.1% TFA for LC-MS/MS analysis.
Samples were analyzed on a Thermo LTQ ion trap mass
spectrometer coupled with an Agilent 1100 series micro-HPLC
system with autosampler essentially as previously described (14).
The mass spectrometer was programmed to target m/z values of
labeled protein kinase peptides previously found to be present in
HuH7 lysates for MS/MS analysis. Quantitative signals for each
labeled protein kinase peptide were derived by extraction of two
to four known fragment ion signals from MS/MS spectra taken at
the corresponding m/z values. The average aggregate fragment
ion signal of duplicate inhibited samples was compared with the
comparable signal from quadruplicate controls to give a percent
inhibition value. A more detailed description of this method will
be published shortly.
Western Blot Analysis.Cells were trypsinized and aliquoted (50,000
cells) into each well of a six-well plate and grown for ≈16 h. For
the turnover assay, cells were ﬁrst treated with MG132 (4 μM)
for 1 h and washed with PBS (100 μL) twice. DMEM containing
2.5% FBS, cycloheximide (50 μg/mL), and the test compound
was added into the well. Cells were harvested after a 2-h chase by
trypsinization and centrifugation at 5000 × g for 4 min at 4 °C.
Cell pellets were resuspended in ice-cold PBS (750 μL), then
centrifuged. Cell pellets were immediately frozen in a −80 °C
freezer and lysed in ice-cold Buffer A [50 mM Tris (pH 7.4), 1%
Triton-X100, 200 mM NaCl, 1 mM EDTA, 2 mM MgCl2, 5 mM
TCEP, 10 mM NEM, protease inhibitor tablet (Roche), and Halt
Phosphatase Inhibitor Mixture (Thermo Scientiﬁc)]. Soluble cell
extract (100 μL for a six-well plate) was mixed with SDS-sample
buffer (4×, 33 μL) and heated at 90 °C for 5 min. After centri-
fugation at 3,000 × g for 30 s, sample (25 or 50 μg) was loaded on
a 4–12% SDS/PAGE. Proteins were transferred to nitro-
ncellulose membranes and stained with Ponceau S. GFP-based
reporters were detected with anti-GFP antibody, and luciferase-
based reporters were detected with anti-luciferase antibody. Cell
extract fractionation was carried out with a nuclear and cyto-
plasmic extraction reagent kit (Thermo Scientiﬁc), and the in-
soluble portion was prepared by dissolving the pellet in SDS-
Urea buffer [4 M Urea, 5% SDS, 100 mM Tris (pH 7.5), 5 mM
EDTA, 0.02% bromophenol blue, and 5 mM DTT].
Plasmid and siRNA Transfection. siRNA oligonucleotides purchased
from Thermo Fisher Scientiﬁc or Qiagen were transfected into
cells using Lipofectamine RNAiMAX (Invitrogen), and plasmids
were transfected using FuGENE HD (Roche), according to the
manufacturers’ protocols.
Cellular Caspase Activity and Cellular Viability. Cells were seeded on
a 384-well solid white plate (5,000 cells/well). Cells were transfected
with luciferase siRNA or p97 siRNA (10 nM) for 48 h or treated
with compounds for the indicated amount of time. Caspase-3/7
Glo, caspase-6Glo, caspase-8Glo, or caspase-9Glo (Promega) was
added into each well and mixed by shaking at 500 rpm for 1 min.
Luminescence signal was determined after incubation at room
temperature for 1 h. Cellular viability was determined with Cell-
Titer-Glo reagent (Promega). To determine the IC50 of cellular
viability, cells were treated with MG132 or DBeQ at seven con-
centrations (threefold serial dilutions starting at 33 μM) for 48 h.
IC50 values were calculated from ﬁtting the percentage of lumi-
nescence signal normalized to DMSO treated cells).
Purchased and Synthesized Compounds. The compounds identiﬁed
as hits from the p97ATPase HTS of the National Institutes of
Health Molecular Libraries Small Molecule Repository were
purchased fromAlbanyMolecularResearch,Aldrich,Chembridge,
ChemDiv, Interchim,PrincetonBioMolecularResearch, andRyan
Scientiﬁc. The purchased compound samples were analyzed and
puriﬁed, as necessary, using reverse-phase (RP) HPLC/UV/MS to
>90% purity as measured by area under the curve at 214 nm.
Myriad 12 and 19 were synthesized according to the published
procedure (2). The oxidized version of Myriad 12 was prepared by
oxidation of Myriad 12 using the 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) procedure. DBeQ was resynthesized as
described previously (15). Compound structures were conﬁrmed
by high resolution mass spectrometry and 1H NMR (Table S7).
General Experimental Section for Small-Molecule Compounds. All
reagents were used as received from the following suppliers: Ark
Pharm, Aldrich Chemistry, and Fisher Scientiﬁc. Acetonitrile and
THF were puriﬁed using the Innovative Technology PureSolv
solvent puriﬁcation system. The 1H and 13C spectra were re-
corded on a Bruker Avance 400 MHz spectrometer. Chemical
shifts are reported in parts per million and were referenced to
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residual proton solvent signals. Flash column chromatography
separations were performed using the Teledyne Isco CombiFlash
Rf using RediSep Rf silica gel columns. TLC was performed on
Analtech UNIPLATE silica gel GHLF plates (gypsum inorganic
hard layer with ﬂuorescence). TLC plates were developed using
iodine vapor. Automated preparative RP HPLC puriﬁcation was
performed using an Agilent 1200 Mass-Directed Fractionation
system (Prep Pump G1361 with gradient extension, Make-up
pump G1311A, pH modiﬁcation pump G1311A, HTS PAL au-
tosampler, UV-DAD detection G1315D, Fraction Collector
G1364B, and Agilent 6120 quadrapole spectrometer G6120A).
The preparative chromatography conditions included a Waters
X-Bridge C18 column (19 × 150 mm, 5 um, with 19 × 10-mm
guard column), elution with a water and acetonitrile gradient,
which increases 20% in acetonitrile content over 4 min at a ﬂow
rate of 20 mL/min (modiﬁed to pH 9.8 through addition of
NH4OH by auxiliary pump), and sample dilution in DMSO. The
preparative gradient, triggering thresholds, and UV wavelength
were selected according to the analytical RP HPLC analysis of
each crude sample. The analytical method used an Agilent 1200
RRLC system with UV detection (Agilent 1200 DAD SL) and
mass detection (Agilent 6224 TOF). The analytical method
conditions included a Waters Aquity BEH C18 column (2.1 × 50
mm, 1.7 um) and elution with a linear gradient of 5% acetonitrile
in pH 9.8 buffered aqueous ammonium formate to 100% aceto-
nitrile at 0.4 mL/min ﬂow rate. Compound purity was measured
on the basis of peak integration (area under the curve) from UV/
vis absorbance (at 214 nm), and compound identity was de-
termined on the basis of mass analysis. All compounds used for
biological studies have purity >90% (Table S7).
Synthesis of Myriad 12, 19, and the Oxidized Version of Myriad 12
(KSC-16-5) (Scheme S1). Myriad 12 and 19 were synthesized
according to the published procedure (2). The oxidized version
of Myriad 12 was prepared by oxidation of Myriad 12 using the
DDQ procedure.
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone (KSC-16-5).
Myriad 12 [(4-(4-chlorophenyl)thiazol-2-ylamino)phenol); 122 mg
(0.40mmol)] was dissolved in 50mLof dichloromethane.DDQ[183
mg (0.80 mmol)] was added. The mixture was stirred at room tem-
perature for 16 h. The solvent was removed, and residuewas puriﬁed
by ﬂash chromatography to give a dark-red solid (110 mg, 91%). 1H
NMR (400 MHz, CDCl3) δ 8.51–8.39 (m, 1H), 7.83–7.70 (m, 2H),
7.63 (s, 1H), 7.41–7.30 (m, 2H), 7.24–7.10 (m, 1H), 6.63 (ddd, J=2.2,
6.3, 10.7Hz, 2H). 13CNMR(101MHz,CDCl3) δ 187.5, 169.8, 157.8,
154.8, 142.2, 134.8, 134.1, 133.2, 132.2, 130.9, 129.2, 127.6, 117.7.
HRMS (m/z): calcd. for C15H10ClN2OS (M+H) 301.0202; found
301.0197.
Synthesized DBeQ (Scheme S2). N-benzyl-2-chloroquinazolin-4-amine.
2,4-dichloroquinazoline (2.4 g, 12.3 mmol) was suspended in
20 mL of THF. Triethylamine (2.1 mL, 14.7 mmol) was added,
followed by the addition of benzylamine (1.4mL, 12.9mmol). The
mixture was stirred at room temperature for 16 h. Themixture was
diluted with EtOAc, ﬁltered, and the ﬁltrate was concentrated.
The residue was puriﬁed by silica gel chromatography (EtOAc:
hexanes = 1:3, Rf = 0.5) to give a colorless solid (1.6 g, 47%). 1H
NMR (400 MHz, CDCl3) δ 7.87–7.73 (m, 2H), 7.68 (d, J= 8.2 Hz,
1H), 7.54–7.32 (m, 6H), 6.10 (s, 1H), 4.90 (d, J = 5.3 Hz, 2H).
N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ, KSC-16-67). To
a suspension of N-benzyl-2-chloroquinazolin-4-amine (30 mg,
0.11 mmol) in CH3CN (1 mL) was added benzylamine (0.025
mL, 0.22 mmol, 2 equiv.). The mixture was heated to 180 °C for 1
h under microwave irradiation. The solvent was removed under
vacuum, the residue was suspended in EtOAc, washed with
saturated NaHCO3, and the layers were separated. The organic
layer was dried over MgSO4 and concentrated under vacuum.
The residue was puriﬁed by silica gel chromatography (EtOAc,
Rf = 0.7) to give a colorless solid (37 mg, 98%). 1H NMR (400
MHz, CDCl3) δ 7.65–7.55 (m, 1H), 7.51 (d, J = 8.3 Hz, 2H),
7.45–7.22 (m, 10H), 7.10 (ddd, J = 1.3, 6.8, 8.1 Hz, 1H), 5.82 (s,
1H), 5.30 (s, 1H), 4.80 (d, J = 5.5 Hz, 2H), 4.76 (d, J = 5.8 Hz,
2H). 13C NMR (101 MHz, CDCl3) 160.1, 159.6, 152.2, 140.1,
138.7, 132.8, 128.7, 128.5, 128.0, 127.6, 127.5, 127.0, 125.7, 121.1,
120.8, 111.1, 45.6, 45.1. HRMS (m/z): calcd for C22H21N4 (M+
H) 341.1766; found 341.1763.
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Fig. S1. DBeQ inhibits p97 ATPase activity independent of aggregate formation. Dynamic light scattering (DLS) was carried out on the Precision Detectors
(PDDLS/CoolBatch 90T). Compounds were diluted to 1× ATPase assay buffer using the same protocol as for conducting ATPase assay. (A) DMSO, (B) clo-
trimazole used as positive control (1), (C) 3.7 μM DBeQ, (D) 11 μM DBeQ, and (E) 33 μM DBeQ. (F) Does–responsive curves of DBeQ on inhibiting ATPase activity
in the presence (black line, 68 nM p97) or in the absence (red line, 250 nM p97) of 0.01% Triton X-100.
1. Seidler J, McGovern SL, Doman TN, Shoichet BK (2003) Identiﬁcation and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem 46:4477–4486.
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Fig. S2. Depletion of p97 stabilizes an endoplasmic reticulum-associated degradation (ERAD) reporter. TCRα-GFP (A) Hek293 cells stably expressing an ERAD
reporter, TCRα-GFP, were assayed by FACS to quantify the degree of reporter accumulation after proteasome inhibition by MG132 (10 μM, 2 h) or p97 de-
pletion by siRNA. (B) Immunoblot analysis of p97 levels and TCRα-GFP accumulation in 293 cells subjected to siRNA directed against luciferase (Luci) or p97. (C)
Degradation of TCRα-GFP was used to determine the effect of DBeQ on the ERAD pathway and was carried out as described in Fig. 1A (main text).
Fig. S3. Western blot to evaluate the protein level of p21. HeLa cells were incubated with 10 μM of MG132 or DBeQ for 5 h. The levels and distributions of p97
and p21 were determined by immunoblotting the cytosolic (Cyto) and nuclear plus membrane (NM) fractions.
Fig. S4. Depletion of p97 stabilizes LC3-II. HeLa cells were transfected with negative control siRNA (NC) or p97 siRNA (10 nM) for 72 h, and the levels and
distributions of the indicated proteins were determined by immunoblotting cytosolic (Cyto), nuclear plus membrane (NM), and insoluble (Ins) fractions.
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Fig. S5. Activation of caspases-3 and -7 and inhibition of cell growth by DBeQ. Time course of caspase-3/7 activity and cellular viability. Upper: RPMI8226 cells
were incubated with the indicated concentrations of drugs for 1, 2, 4, 6, 8, 9, or 21 h before determination of caspases-3 plus -7 activities in total cell lysate.
Lower: Cellular viability was determined using CellTiter-Glo after 3-, 6-, 8-, or 20-h incubation with drugs.
Fig. S6. Activation of caspases-3 and -7. (A–C) Same as Fig. S5, except MCF7, HCT116 WT, and HCT116 p53−/− cells were used, respectively.
Fig. S7. Western blot to evaluate degradation of ODD-Luc by Myriad 12 and 19. HeLa cells stably expressing the UbG76V-GFP and ODD-Luc reporters were
grown in six-well plates. Cells were treated with MG132 (4 μM for 1 h) to accumulate reporter, washed, and exposed to the indicated test compounds plus
cycloheximide to initiate a chase. After 2 h, cells were harvested and evaluated by immunoblotting for the remaining ODD-Luc. The Ponceau S-stained ﬁlter
serves as loading controls.
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Table S1. Hits from two HTS screens for p97 inhibitors
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Table S1. Cont.
*Measurements were carried out in triplicate, and variance is expressed as the SE.
†Compounds with PubChem CID number are hits from the National Institutes of Health Molecular Libraries Small
Molecule Repository. The remaining compounds are from the Maybridge HitFinder collection.
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Table S3. Plasmids used in this study
Plasmid no. Plasmid name Vector Source and Reference
RDB2003 Murine p97-myc His/pcDNA4 TO pcDNA4.1 TO (Invitrogen) (1)
RDB2004 Murine p97 E578Q -myc His/pcDNA4 TO pcDNA4.1 TO (Invitrogen) (1)
RDB2120 Murine p97-pET28a pET28a (Novagen) (2)
RDB2122 Hamster NSF-pHisTrcHis-Flag-Myc pHisTrcHis (Invitrogen) Y. Ye*
RDB2402 C522A-p97-PET28a/DH5a pET28a (Novagen) (3)
RDB2405 QQmp97-myc His/pcDNA4.1TOsiRNA pcDNA4.1 TO (Invitrogen) (3)
*Provided by Y. Ye (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health, Bethesda, MD).
Table S4. Cell lines used in this study
Cell line no. Cell line name Source and reference
DTC7 RPMI-8226 ATCC no. CCL-155
DTC12 TCRα-GFP/293 R. R. Kopito (1)
DTC22 HeLa ATCC no. CCL 2
DTC23 UbG76V-GFP/Luc-ODC/HeLa (2)
DTC25 UbG76V-GFP/ODD-Luc/HeLa (2)
DTC44 HCT116 WT B. Vogelstein (3)
DTC45 HCT116 p53−/− B. Vogelstein (3)
DTC63 MCF7 ATCC no. HTB-22
DTC65 Hek293 ATCC no. CRL1573
DTC69 MRC5 Coriell Institute AG-05965E
1. DeLaBarre B, Christianson JC, Kopito RR, Brunger AT (2006) Central pore residues mediate the p97/VCP activity required for ERAD. Mol Cell 22:451–462.
2. Chou TF, Deshaies RJ (2011) Quantitative cell-based proteindegradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem, in press.
3. Bunz FD, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501.
Table S2. Published chemical inhibitors of p97
*Measurements were carried out in triplicate, and variance is expressed as the SD.
†Myriad 12 and 19 were readily oxidized to forms with similar activity as parent compounds.
‡Oxidized form of Myriad 12 was independently synthesized and tested.
1. Dalal S, Rosser MF, Cyr DM, Hanson PI (2004) Distinct roles for the AAA ATPases NSF and p97 in the secretory pathway. Mol Biol Cell 15:637–648.
2. DeLaBarre B, Brunger AT (2003) Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat Struct Biol 10:856–863.
3. Chou TF, Deshaies RJ (2011) Quantitative cell-based proteindegradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem, in press.
Table S5. siRNAs used in this study
Target gene Catalog no.
Luciferase Thermo Fisher Scientiﬁc P-002099–01-20
p97/VCP Thermo Fisher Scientiﬁc D008727060050
None Negative control siRNA (Qiagen 1027310)
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Table S6. Compound identiﬁer, purity, and HRMS data for purchased and synthesized compounds
Cpd ID KSC lot no. PubChem CID PubChem SID Purity % HRMS calcd. HRMS found
1 KSC-16-67 676352 93575591 100.0 341.1766 341.1763
2 KSC-1-150 886813 87796231 100.0 330.1406 330.1408
3 NA
4 KSC-1-127 6763 87326022 98.8 209.0602 209.0605
5 NA
6 NA
7 NA
8 NA
9 NA
10 NA
11 KSC-1-132 2939678 87334034 435.0320 Insufﬁcient target
12 KSC-1-130 9586497 87334033 52.6 (partially hydrolyzed)* 337.0623 337.0615
13 KSC-1-204 3500086 87796244 100.0 444.0145 444.0133
14 NA
15 KSC-1-131 9567210 87326025 97.4 322.1304 322.1296
16 KSC-1-128 987585 87326023 100.0 438.1121 438.1111
17 NA
18 NA
19 NA
20 KSC-1-129 801956 87326024 97.9 329.0960 329.0955
21 NA
22 NA
23 NA
24 NA
25 NA
26 NA
27 NA
28 NA
29 NA
30 NA
31 KSC-1-206 2384538 87796246 100.0 234.0434 234.0429
32 KSC-1-202 2810445 87796242 Hydrolyzed* 349.9987
33 NA
34 KSC-1-201 2810155 87796241 100.0 317.0418 317.0411
35 KSC-1-209 2472581 92093138 94.2 331.0388 331.0388
36 KSC-1-199 4072379 87796243 95.7 346.1191 346.1187
37 NA
38 NA
39 NA
40 NA
41 NA
42 NA
43 NA
44 KSC-1-133 5559718 87326026 95.6 339.0626 339.0617
45 KSC-1-205 5982653 87796245 Hydrolyzed* 369.0505 Insufﬁcient target
46 KSC-1-232 3787408 92093144 97.0 535.1473 535.1466
47 KSC-1-233 2044030 92093145 97.8 449.0839 449.0829
48 NA
49 NA
50 NA
Myriad 12 KSC-1-275 697280 92093146 91.4 269.0748 269.0744
Myriad 19 KSC-1-277 753704 92093147 90.2 303.0359 303.0343
Oxidized Myriad 12 KSC-16-5 45281169 92764872 95.1 301.0202 301.0197
Cpd, compound; KSC, University of Kansas Specialized Chemistry Center; CID, compound identiﬁer; SID, substance accession identiﬁer.
*Hydrolyzed: compound is not stable under basic LC conditions.
Other Supporting Information Files
Dataset S1 (XLS)
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